Reata’s RTA 402 receives orphan drug status from FDA
The U.S. Food and Drug Administration has granted orphan drug designation to Reata Pharmaceuticals, Inc.’s RTA 402 for treating patients suffering from pancreatic cancer. Currently in Phase 1/2 of its trial, RTA 402 receives economic incentive for further development in the form of reduction/exemption in regulatory fees, seven years of exclusivity in market and other support from FDA for R&D initiatives.
- FDA grants orphan drug status to treatment for cancer
- BioSante Announces FDA Orphan Drug Designation For GVAX Chronic Myeloid Leukemia Cancer Vaccine
- GlaxoSmithKline receives FDA approval for advanced renal cell carcinoma treatment
- Teva receives approval for generic Eloxatin
